Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Voriconazole.

Rahul Naithani1, Rajat Kumar

  • 1Department of Hematology, All India Institute of Medical Sciences, New Delhi 110 029, India. dr_rahul6@hotmail.com

Indian Pediatrics
|January 21, 2006
PubMed
Summary
This summary is machine-generated.

Voriconazole is a potent antifungal drug effective against Aspergillus and Candida infections. It offers a safer alternative to Amphotericin B, with oral formulations reducing hospital stays.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.

JCO oncology practice·2026
Same author

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2026
Same author

The CCCH-type zinc-finger <i>Pf</i> MD3 promotes translation for malaria parasite transmission.

bioRxiv : the preprint server for biology·2026
Same author

ATAD3 megadalton complex in Plasmodium falciparum is essential for mitochondrial and cellular viability.

PLoS pathogens·2026
Same author

Dominant Role of Electron-Electron Scattering in the Photoinduced Terahertz Conductivity Spectra of Few-Layer WS<sub>2(1-<i>x</i>)</sub>Se<sub>2<i>x</i></sub> Flakes.

ACS nano·2026
Same author

Prior Malignancy History and Risk of Second Malignancies After Allogeneic Hematopoietic Cell Transplantation.

Transplantation and cellular therapy·2026
Same journal

Prevalence and Associated Social Factors of Prediabetes in Children and Adolescents in India: A Systematic Review and Meta-Analysis.

Indian pediatrics·2026
Same journal

Comparison of Early Intrapleural Fibrinolytic Therapy, Versus Administration After Failure of Intercostal Drainage in Children with Empyema Thoracis: A Systematic Review.

Indian pediatrics·2026
Same journal

Can Nebulized Epinephrine Prevent Extubation Failure in Neonates?

Indian pediatrics·2026
Same journal

Pragmatic Respiratory Stabilization During Neonatal Intubation-What Does this Trial Add for Indian NICUs?

Indian pediatrics·2026
Same journal

Universal Early-Life Screening in India: Time for a National Integrated Strategy.

Indian pediatrics·2026
Same journal

Transparent Film Dressing Versus Microporous Paper Tape for Temperature Probe Fixation in Preterm Neonates: A Randomized Controlled Trial.

Indian pediatrics·2026
See all related articles

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Voriconazole (VRZ) is a second-generation triazole antifungal.
  • It targets ergosterol synthesis, crucial for fungal cell membranes.
  • Effective against Aspergillus and Candida species.

Purpose of the Study:

  • To evaluate the efficacy and safety of Voriconazole.
  • To compare Voriconazole with Amphotericin B.
  • To assess the impact of oral Voriconazole on hospital stay duration.

Main Methods:

  • Literature review of clinical studies on Voriconazole.
  • Pharmacokinetic and pharmacodynamic analysis.
  • Comparative safety and toxicity assessments.

Related Experiment Videos

Main Results:

  • Voriconazole demonstrates broad-spectrum antifungal activity.
  • Exhibits reduced nephrotoxicity and infusion-related toxicity compared to Amphotericin B.
  • Similar pharmacokinetics between oral and parenteral formulations.
  • Oral VRZ shortens hospital stay duration.
  • Generally well-tolerated with notable drug interactions.

Conclusions:

  • Voriconazole is a well-tolerated and effective antifungal agent.
  • Offers a favorable safety profile over Amphotericin B.
  • Oral formulation enhances patient management and reduces healthcare costs.